Oi Shan Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Oi Shan Tang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Pak Chung Ho
14 shared publicationsSharon W.H. Lee
Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
7 shared publications- Ernest Hung Yu Ng
The University of Hong Kong
6 shared publications - Pak Chung Ho
Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
3 shared publications Carina C.W. Chan
The University of Hong Kong, Hong Kong SAR, Hong Kong Special Administrative Region of China
2 shared publicationsJieshuang Xu
2 shared publications
Latest Publications
- 25 September 2012
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 40 (4) , 392-397
Effect of letrozole on uterine artery Doppler flow indices prior to first‐trimester termination of pregnancy: a randomized controlled trial
Objective We previously demonstrated that a sequential regimen of letrozole and misoprostol resulted in a marked reduction in the serum estradiol concentration and in a higher efficacy of first‐trimester termination of pregnancy than misoprostol alone. The aim of this study was to evaluate the effect of letrozole on uterine artery Doppler flow indices during early pregnancy. Methods This was a randomized controlled trial. Thirty women requesting termination of pregnancy up to 63 days' gestation were randomized into two groups: a letrozole group receiving 10 mg of letrozole, daily, for 3 days, and a control group receiving a placebo for 3 days. Serum estradiol, progesterone and human chorionic gonadotropin (hCG) concentrations were measured before drug administration and then daily for 6 days. Ultrasound scanning for fetal viability and measurement of the pulsatility (PI) and resistance (RI) indices of the uterine arteries was performed before drug administration, and then on day 3 and day 7 after starting letrozole or placebo. All pregnancies were terminated by surgical evacuation on day 7 or day 8. Results Uterine artery PI and RI decreased significantly in the letrozole group, but not in the control group. Serum estradiol concentrations were significantly lower in the letrozole group than in the control group from day 2 onwards. Serum progesterone and hCG concentrations were comparable for the two groups throughout the 7 days. There were significantly more women in the letrozole group with vaginal bleeding. Conclusion We have demonstrated that the use of letrozole in the first trimester of pregnancy suppresses serum estradiol levels but results in an increase in blood flow to the uterus. Further studies should be carried out to elucidate the mechanism of letrozole pretreatment in medical abortion. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.
- 25 September 2012
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 40 (4) , 392-397
Effect of letrozole on uterine artery Doppler flow indices prior to first‐trimester termination of pregnancy: a randomized controlled trial
Objective We previously demonstrated that a sequential regimen of letrozole and misoprostol resulted in a marked reduction in the serum estradiol concentration and in a higher efficacy of first‐trimester termination of pregnancy than misoprostol alone. The aim of this study was to evaluate the effect of letrozole on uterine artery Doppler flow indices during early pregnancy. Methods This was a randomized controlled trial. Thirty women requesting termination of pregnancy up to 63 days' gestation were randomized into two groups: a letrozole group receiving 10 mg of letrozole, daily, for 3 days, and a control group receiving a placebo for 3 days. Serum estradiol, progesterone and human chorionic gonadotropin (hCG) concentrations were measured before drug administration and then daily for 6 days. Ultrasound scanning for fetal viability and measurement of the pulsatility (PI) and resistance (RI) indices of the uterine arteries was performed before drug administration, and then on day 3 and day 7 after starting letrozole or placebo. All pregnancies were terminated by surgical evacuation on day 7 or day 8. Results Uterine artery PI and RI decreased significantly in the letrozole group, but not in the control group. Serum estradiol concentrations were significantly lower in the letrozole group than in the control group from day 2 onwards. Serum progesterone and hCG concentrations were comparable for the two groups throughout the 7 days. There were significantly more women in the letrozole group with vaginal bleeding. Conclusion We have demonstrated that the use of letrozole in the first trimester of pregnancy suppresses serum estradiol levels but results in an increase in blood flow to the uterus. Further studies should be carried out to elucidate the mechanism of letrozole pretreatment in medical abortion. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.
- Top Cited Papers
- 26 October 2007
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 99 (S2) , S160-7
Misoprostol: Pharmacokinetic profiles, effects on the uterus and side‐effects
Misoprostol, a synthetic prostaglandin E1 analogue, is commonly used for medical abortion, cervical priming, the management of miscarriage, induction of labor and the management of postpartum hemorrhage. It can be given orally, vaginally, sublingually, buccally or rectally. Studies of misoprostol's pharmacokinetics and effects on uterine activity have demonstrated the properties of the drug after various routes of administration. These studies can help to discover the optimal dose and route of administration of misoprostol for individual clinical applications. Misoprostol is a safe drug but serious complications and teratogenicity can occur with unsupervised use.
- 26 October 2007
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 99 (S2) , S160-7
Top Cited PapersMisoprostol: Pharmacokinetic profiles, effects on the uterus and side‐effects
Misoprostol, a synthetic prostaglandin E1 analogue, is commonly used for medical abortion, cervical priming, the management of miscarriage, induction of labor and the management of postpartum hemorrhage. It can be given orally, vaginally, sublingually, buccally or rectally. Studies of misoprostol's pharmacokinetics and effects on uterine activity have demonstrated the properties of the drug after various routes of administration. These studies can help to discover the optimal dose and route of administration of misoprostol for individual clinical applications. Misoprostol is a safe drug but serious complications and teratogenicity can occur with unsupervised use.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 18 (6) , 581-586
The use of misoprostol for early pregnancy failure
This paper reviews the current management of early pregnancy failure with particular emphasis on the use of misoprostol. Medical management using misoprostol is effective for the management of miscarriages. The success rate ranged from 84 to 93% depending on the regimen of misoprostol, the duration of waiting period and the types of miscarriage. Miscarriages occur in 10 to 20% of all pregnancies. Surgical evacuation has been used to empty the uterus. Recently, medical treatment using misoprostol has been studied for the management of miscarriage. It avoids surgery and its associated complications. Compared to expectant management, the success rate is higher. Nonsurgical management takes a longer period to reach the endpoint and medical management is associated with side effect of medication. Studies have shown that medical management is safe and acceptable to women. The optimal regimen of medical management, however, is yet to be determined.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 18 (6) , 581-586
The use of misoprostol for early pregnancy failure
This paper reviews the current management of early pregnancy failure with particular emphasis on the use of misoprostol. Medical management using misoprostol is effective for the management of miscarriages. The success rate ranged from 84 to 93% depending on the regimen of misoprostol, the duration of waiting period and the types of miscarriage. Miscarriages occur in 10 to 20% of all pregnancies. Surgical evacuation has been used to empty the uterus. Recently, medical treatment using misoprostol has been studied for the management of miscarriage. It avoids surgery and its associated complications. Compared to expectant management, the success rate is higher. Nonsurgical management takes a longer period to reach the endpoint and medical management is associated with side effect of medication. Studies have shown that medical management is safe and acceptable to women. The optimal regimen of medical management, however, is yet to be determined.
- 1 July 2006
- Published by Elsevier in Contraception
- Vol. 74 (1) , 26-30
The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion
- 1 July 2006
- Published by Elsevier in Contraception
- Vol. 74 (1) , 26-30
The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion
- 1 January 2006
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 22 (12) , 655-659
Clinical applications of mifepristone
Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and various cancers have been explored. However, its association with abortion limits the applications of mifepristone in many of these areas.
- 1 January 2006
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 22 (12) , 655-659
Clinical applications of mifepristone
Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog. It is also an effective cervical priming agent that can be used to soften the cervix before surgical evacuation. Its clinical efficacy as an emergency contraception has been proven. Other applications including treatment for fibroids, endometriosis and various cancers have been explored. However, its association with abortion limits the applications of mifepristone in many of these areas.
- Open Access
- 9 September 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (1) , 189-192
A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage
BACKGROUND: This randomized controlled trial compared the use of sublingual misoprostol with or without an additional 1 week course of sublingual misoprostol for the medical management of silent miscarriage. METHODS: A total of 180 women who had silent miscarriage (P < 0.01) in the group with an extended course of sublingual misoprostol. Other side-effects were similar. CONCLUSION: Sublingual misoprostol is useful for the management of silent miscarriage. An additional 1 week course of sublingual misoprostol did not improve the success rate or shorten the duration of vaginal bleeding. Instead, it increased the incidence of diarrhoea.
- 9 September 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (1) , 189-192
Open AccessA randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage
BACKGROUND: This randomized controlled trial compared the use of sublingual misoprostol with or without an additional 1 week course of sublingual misoprostol for the medical management of silent miscarriage. METHODS: A total of 180 women who had silent miscarriage (P < 0.01) in the group with an extended course of sublingual misoprostol. Other side-effects were similar. CONCLUSION: Sublingual misoprostol is useful for the management of silent miscarriage. An additional 1 week course of sublingual misoprostol did not improve the success rate or shorten the duration of vaginal bleeding. Instead, it increased the incidence of diarrhoea.
- Open Access
- 21 July 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (11) , 3062-3066
A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12–20 weeks gestation
BACKGROUND: Sublingual misoprostol has been shown to be effective in medical abortion. A prospective double-blinded placebo-controlled trial was done to compare the efficacy and side-effects of sublingual to oral misoprostol when used with mifepristone for medical abortion from 12 to 20 weeks gestation. METHODS: A total of 120 women at 12–20 weeks of gestation were randomized to receive 200 mg oral mifepristone followed by either sublingual or oral misoprostol 400 mg every 3 h for a maximum of five doses 36–48 h later. The course of misoprostol was repeated if the woman did not abort within 24 h. RESULTS: There was no significant difference (P = 0.43) in the success rate at 24 h [relative risk = 1.075; 95% confidence interval (CI): 0.94–1.19]. Abortion occurred in 91.4% in the sublingual group (95% CI: 81.0–96.7%) as compared to 85.0% (95% CI: 73.7–92.1%) in the oral group. The median induction-to-abortion interval was significantly shorter (P = 0.009) in the sublingual group (5.5 h) as compared to the oral group (7.5 h). The incidence of fever was higher in the sublingual group (P < 0.0001). The incidences of other side-effects were similar. CONCLUSION: Sublingual misoprostol, when combined with mifepristone, is effective for medical abortion in the second trimester. The induction-to-abortion interval is shorter when sublingual misoprostol is used when compared to oral misoprostol.
- 21 July 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (11) , 3062-3066
Open AccessA prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12–20 weeks gestation
BACKGROUND: Sublingual misoprostol has been shown to be effective in medical abortion. A prospective double-blinded placebo-controlled trial was done to compare the efficacy and side-effects of sublingual to oral misoprostol when used with mifepristone for medical abortion from 12 to 20 weeks gestation. METHODS: A total of 120 women at 12–20 weeks of gestation were randomized to receive 200 mg oral mifepristone followed by either sublingual or oral misoprostol 400 mg every 3 h for a maximum of five doses 36–48 h later. The course of misoprostol was repeated if the woman did not abort within 24 h. RESULTS: There was no significant difference (P = 0.43) in the success rate at 24 h [relative risk = 1.075; 95% confidence interval (CI): 0.94–1.19]. Abortion occurred in 91.4% in the sublingual group (95% CI: 81.0–96.7%) as compared to 85.0% (95% CI: 73.7–92.1%) in the oral group. The median induction-to-abortion interval was significantly shorter (P = 0.009) in the sublingual group (5.5 h) as compared to the oral group (7.5 h). The incidence of fever was higher in the sublingual group (P < 0.0001). The incidences of other side-effects were similar. CONCLUSION: Sublingual misoprostol, when combined with mifepristone, is effective for medical abortion in the second trimester. The induction-to-abortion interval is shorter when sublingual misoprostol is used when compared to oral misoprostol.
- Open Access
- 1 March 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (3) , 829-833
Intracervical sodium nitroprusside versus vaginal misoprostol in first trimester surgical termination of pregnancy: a randomized double-blinded controlled trial
Results from small-scale randomized studies on the effectiveness of different preparations of nitric oxide donors in cervical priming before first trimester termination of pregnancies are not consistent. We compared sodium nitroprusside gel to misoprostol, the standard agent for cervical priming in this randomized double-blinded controlled trial.
- 1 March 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (3) , 829-833
Open AccessIntracervical sodium nitroprusside versus vaginal misoprostol in first trimester surgical termination of pregnancy: a randomized double-blinded controlled trial
Results from small-scale randomized studies on the effectiveness of different preparations of nitric oxide donors in cervical priming before first trimester termination of pregnancies are not consistent. We compared sodium nitroprusside gel to misoprostol, the standard agent for cervical priming in this randomized double-blinded controlled trial.
- Open Access
- 25 March 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (5) , 1101-1104
A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester
BACKGROUND: Misoprostol is an effective agent for pre‐operative cervical priming before surgical termination of pregnancy in the first trimester. Previous studies have shown that both oral and vaginal routes are equally effective for such a purpose. This study aimed to compare a new route of sublingual administration to the vaginal route of administration for pre‐operative cervical priming in first trimester surgical abortion. METHODS: Eighty women with gestational age <12 weeks were randomized by a computer‐generated model to receive 400 µg of misoprostol either sublingually or vaginally 3 h prior to vacuum aspiration. The primary outcome measure was the degree of cervical dilatation, and secondary outcomes included the force required to dilate the cervix from 3 to 8 mm, intra‐operative blood loss and incidence of pre‐operative side‐effects. RESULTS: There was no significant difference in the baseline cervical dilatation (sublingual: 7.6 ± 1.3 mm; vaginal: 7.7 ± 0.73 mm), cumulative force required to dilate the cervix from 3 to 8 mm (sublingual: 9.0 ± 9.8 N; vaginal: 6.6 ± 5.4 N) and total blood loss (sublingual: 52.1 ± 20.2 ml; vaginal: 48.3 ± 12.3 ml). Pre‐operative side‐effects were also similar. CONCLUSIONS: Both sublingual and vaginal misoprostol are effective in cervical priming before surgical termination of pregnancy in the first trimester. Sublingual misoprostol has the advantage of being more convenient to administer and may be more suitable for day surgery.
- 25 March 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (5) , 1101-1104
Open AccessA randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester
BACKGROUND: Misoprostol is an effective agent for pre‐operative cervical priming before surgical termination of pregnancy in the first trimester. Previous studies have shown that both oral and vaginal routes are equally effective for such a purpose. This study aimed to compare a new route of sublingual administration to the vaginal route of administration for pre‐operative cervical priming in first trimester surgical abortion. METHODS: Eighty women with gestational age <12 weeks were randomized by a computer‐generated model to receive 400 µg of misoprostol either sublingually or vaginally 3 h prior to vacuum aspiration. The primary outcome measure was the degree of cervical dilatation, and secondary outcomes included the force required to dilate the cervix from 3 to 8 mm, intra‐operative blood loss and incidence of pre‐operative side‐effects. RESULTS: There was no significant difference in the baseline cervical dilatation (sublingual: 7.6 ± 1.3 mm; vaginal: 7.7 ± 0.73 mm), cumulative force required to dilate the cervix from 3 to 8 mm (sublingual: 9.0 ± 9.8 N; vaginal: 6.6 ± 5.4 N) and total blood loss (sublingual: 52.1 ± 20.2 ml; vaginal: 48.3 ± 12.3 ml). Pre‐operative side‐effects were also similar. CONCLUSIONS: Both sublingual and vaginal misoprostol are effective in cervical priming before surgical termination of pregnancy in the first trimester. Sublingual misoprostol has the advantage of being more convenient to administer and may be more suitable for day surgery.
- Open Access
- 1 January 2004
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 83 (7) , 647-650
A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor
Background. To compare sublingual misoprostol with intravenous syntometrine use during third stage of labor by measuring the blood loss. Methods. Sixty women were randomized to receive either 600 µg misoprostol sublingually or 1 ml syntometrine intravenously during the third stage of labor after spontaneous vaginal delivery. For those with risk factors of postpartum hemorrhage such as medical induction or augmentation of labor, previous third stage complications were excluded. The blood loss in labor was measured by the alkaline–hematin method, and differences in hemoglobin before and after delivery were compared. Results. There was no significant difference in the median measured blood loss between the misoprostol group and the syntometrine group (280 versus 226 ml, p = 0.45). The change in hemoglobin was comparable between the two groups. There were more women in the misoprostol group who required additional oxytocics, but the difference was not statistically significant. A major complication occurred in one patient in the misoprostol group with blood loss in excess of 1000 ml. The incidence of side effects such as shivering and pyrexia in women receiving misoprostol was significantly higher than that in the syntometrine group. Conclusion. The use of sublingual misoprostol or intravenous syntometrine in spontaneous vaginal delivery resulted in a comparable amount of blood loss. Transient side effect such as fever and shivering which resolved within a day occurred more frequent to those who received sublingual misoprostol.
- 1 January 2004
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 83 (7) , 647-650
Open AccessA pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor
Background. To compare sublingual misoprostol with intravenous syntometrine use during third stage of labor by measuring the blood loss. Methods. Sixty women were randomized to receive either 600 µg misoprostol sublingually or 1 ml syntometrine intravenously during the third stage of labor after spontaneous vaginal delivery. For those with risk factors of postpartum hemorrhage such as medical induction or augmentation of labor, previous third stage complications were excluded. The blood loss in labor was measured by the alkaline–hematin method, and differences in hemoglobin before and after delivery were compared. Results. There was no significant difference in the median measured blood loss between the misoprostol group and the syntometrine group (280 versus 226 ml, p = 0.45). The change in hemoglobin was comparable between the two groups. There were more women in the misoprostol group who required additional oxytocics, but the difference was not statistically significant. A major complication occurred in one patient in the misoprostol group with blood loss in excess of 1000 ml. The incidence of side effects such as shivering and pyrexia in women receiving misoprostol was significantly higher than that in the syntometrine group. Conclusion. The use of sublingual misoprostol or intravenous syntometrine in spontaneous vaginal delivery resulted in a comparable amount of blood loss. Transient side effect such as fever and shivering which resolved within a day occurred more frequent to those who received sublingual misoprostol.